Related Experiment Video

Updated: Jan 29, 2026

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.7K

The relevance of microRNA in post-infarction left ventricular remodelling and heart failure

Mieczysław Dutka1, Rafał Bobiński2, Jan Korbecki2

  • 1Department of Biochemistry and Molecular Biology, University of Bielsko-Biala, Faculty of Health Sciences, Willowa St. 2, 43-309, Bielsko-Biała, Poland. mdutka@ath.bielsko.pl.

Heart Failure Reviews
|February 3, 2019
PubMed

Insights

MicroRNAs show promise as early biomarkers for predicting adverse left ventricular remodelling and heart failure after myocardial infarction. Research highlights their stability in circulation and altered levels in patients, aiding risk stratification.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biomarker Discovery

Background:

  • Myocardial infarction (MI) and subsequent left ventricular (LV) remodelling pose significant morbidity and mortality risks.
  • Identifying patients at high risk for adverse LV remodelling and dysfunction post-MI is crucial for timely intervention.
  • MicroRNAs (miRNAs) are increasingly recognized for their critical roles in cardiovascular diseases.

Purpose of the Study:

  • To summarize current knowledge on the significance of microRNAs in post-infarction LV remodelling.
  • To explore the potential of miRNAs as early biomarkers for identifying high-risk patients.
  • To review the role of miRNAs in predicting the development of heart failure after MI.

Main Methods:

  • Literature review of experimental data and clinical studies on microRNAs in cardiovascular diseases.
  • Analysis of research on miRNA stability in systemic circulation and their detectability in blood.
  • Examination of studies reporting changes in miRNA concentrations in MI and heart failure patients.

Main Results:

  • MicroRNAs are stable in circulation and measurable in patient blood, indicating their potential as accessible biomarkers.
  • Significant alterations in specific miRNA concentrations are observed in patients with myocardial infarction and heart failure.
  • MicroRNAs are being investigated as potential markers for cardiomyocyte necrosis and predictors of post-infarction heart failure.

Conclusions:

  • MicroRNAs hold significant potential as valuable biomarkers for assessing post-infarction left ventricular remodelling.
  • Further research into microRNAs could lead to improved early detection and management strategies for heart failure post-MI.
  • MicroRNA profiling may offer a novel approach for risk stratification in patients following myocardial infarction.
Keywords:
Heart failureLeft ventricular remodellingMicroRNAMyocardial fibrosisMyocardial infarction

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963